ACC: SGLT2 inhibitors, GLP-1 agonists reduce CV risk in type 2 diabetes

Recent studies have shown that sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists significantly improve CV outcomes, according to an American College of Cardiology expert consensus decision pathway published in the Jo https://www.healio.com/cardiology/chd-prevention/news/online/%7B34f9e872-4842-4d5a-bfe9-fcdb050a5410%7D/acc-sglt2-inhibitors-glp-1-agonists-reduce-cv-risk-in-type-2-diabetes